| Edizione | [1st ed. 2021.] |
| Pubbl/distr/stampa |
Gateway East, Singapore : , : Springer, , [2021]
|
| Descrizione fisica |
1 online resource (X, 352 p. 59 illus., 41 illus. in color.)
|
| Disciplina |
616.994
|
| Collana |
Respiratory Disease Series: Diagnostic Tools and Disease Managements
|
| Soggetto topico |
Mesothelioma
|
| ISBN |
981-15-9158-X
|
| Formato |
Materiale a stampa  |
| Livello bibliografico |
Monografia |
| Lingua di pubblicazione |
eng
|
| Nota di contenuto |
Part I Epidemiology -- 1. Recent Trends in the Global Incidence of Mesothelioma: What is the Relationship with an Asbestos Ban? -- Part II Pathogenesis -- 2. Asbestos and mesothelioma: What is recent advance in research on asbestos-induced molecular carcinogenesis? -- 3. Asbestos fiber and immunological effects: Do immunological effects play any role in asbestos-related diseases? -- 4. Biomolecular pathways in mesothelioma: What is new perspective on biomolecular research for mesothelioma? -- Part III Screening and early detection -- 5. Biomarkers for mesothelioma screening: How can we identify subjects developing mesothelioma in asbestos-exposed high-risk group? -- 6. Pleural Plaques as a predictive imaging marker for cancer screening in asbestos-exposed subjects: Can pleural plaques be a tool beyond estimating past asbestos inhalation? -- Part IV Pathology -- 7. Anatomical structure of the pleura and mesothelial cells: What are the characteristic features? -- 8. Histologic classification of tumors of the pleura: Advances after WHO 2015 classification -- 9. Pathology of mesothelioma, subtypes and rare variants: What is the role of immunohistochemical markers in differential diagnosis? -- 10. Cytopathologic diagnosis of mesothelioma: Can we diagnose mesothelioma based on fluid cytological materials without biopsy? -- 11. Circulating tumor cells in malignant pleural mesothelioma: What is the role of liquid biopsy in clinical practice of malignant pleural mesothelioma? -- Part V Molecular Genetics -- 12. Recent advances on the pathogenesis of mesothelioma in genetics and genomics: What are novel insights into mesothelioma biology? -- 13. Genetic predisposition to mesothelioma: What are the biological mechanisms and what are the clinical characteristics of these mesotheliomas? -- 14. Frequent NF2 inactivation in mesothelioma: How can we treat mesothelioma with targeted therapies for molecular aberrations? -- Part VI Clinical Features and Management -- 15. Use of Tunneled Catheters versus Pleurodesis for Mesothelioma: When should we use one or the other, or both? -- 16. Advanced minimally invasive approach with medical thoracoscopy for mesothelioma: What are the roles in diagnosis? -- 17. Imaging evaluation of local tumor growth in malignant pleural mesothelioma: What is the role of imaging modalities in curative intent surgery for mesothelioma? -- 18. 18F-Fluorodeoxyglucose positron emission tomography/computed tomography in malignant pleural mesothelioma: What is the role in mesothelioma detection and treatment response assessment? -- 19. Palliation in malignant pleural mesothelioma: How to manage clinical symptoms in mesothelioma -- 20. Supportive care for advanced mesothelioma: What is the role of mesothelioma nurses in clinical practice? -- Part VII Treatment; Current standard and future perspective -- 21. Antiangiogenic therapies for mesothelioma: What is the role in mesothelioma treatment? -- 22. Systemic chemotherapy for unresectable pleural mesothelioma from frontline to salvage treatment : How can we treat the patients failed to PD-1/PD-L1 inhibitors? -- 23. Biomarkers for Immune checkpoint inhibitors in mesothelioma: What are the roles of biomarkers for optimal immune therapy? -- 24. Promising investigational new drugs for mesothelioma: What is the next stage of the treatment for advanced mesothelioma? -- 25. Viral immune therapy and other virotherapies for advanced mesothelioma: Are we ready for clinical trials of viral immune therapy? -- Part VIII Radiotherapy -- 26. Impact of Radiation Therapy on Malignant Mesothelioma: Are we ready for use in clinical practice, combined with surgery or alone? -- Part IX. Surgical Intervention; Current status and future perspectives -- 27. TNM classification and the role of curative intent surgery for mesothelioma: Is the debate on extra-pleural pneumonectomy versus lung-sparing macroscopic resection over? -- 28. Surgery and adjuvant or neoadjuvant setting of radiotherapy: What is the role of radiotherapy in combination with lung-sparing surgery? -- 29. Loco-regional treatment with surgical intervention in mesothelioma: What is the role of enhancing local control approaches?.
|
| Record Nr. | UNINA-9910484289203321 |
Info
Brachytherapy : Techniques and Evidences / / edited by Yasuo Yoshioka, Jun Itami, Masahiko Oguchi, Takashi Nakano